Feminizing Hormone and Side Effects
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A History of Birth Control Methods
Report Published by the Katharine Dexter McCormick Library and the Education Division of Planned Parenthood Federation of America 434 West 33rd Street, New York, NY 10001 212-261-4716 www.plannedparenthood.org Current as of January 2012 A History of Birth Control Methods Contemporary studies show that, out of a list of eight somewhat effective — though not always safe or reasons for having sex, having a baby is the least practical (Riddle, 1992). frequent motivator for most people (Hill, 1997). This seems to have been true for all people at all times. Planned Parenthood is very proud of the historical Ever since the dawn of history, women and men role it continues to play in making safe and effective have wanted to be able to decide when and whether family planning available to women and men around to have a child. Contraceptives have been used in the world — from 1916, when Margaret Sanger one form or another for thousands of years opened the first birth control clinic in America; to throughout human history and even prehistory. In 1950, when Planned Parenthood underwrote the fact, family planning has always been widely initial search for a superlative oral contraceptive; to practiced, even in societies dominated by social, 1965, when Planned Parenthood of Connecticut won political, or religious codes that require people to “be the U.S. Supreme Court victory, Griswold v. fruitful and multiply” — from the era of Pericles in Connecticut (1965), that finally and completely rolled ancient Athens to that of Pope Benedict XVI, today back state and local laws that had outlawed the use (Blundell, 1995; Himes, 1963; Pomeroy, 1975; Wills, of contraception by married couples; to today, when 2000). -
A Handy Guide to the Male and Female Reproductive Tracts
BASICS OF LIFE BY LES SELLNOW eproduction in all species borders on the miraculous. at the reproductive organs of both the mare and the stallion How else can one describe a process where two infini- and discuss just how they function in their effort to produce Rtesimal entities, one from the male, the other from the another “miracle.” Once again, sources are too numerous to female, join forces to produce living, breathing offspring? mention, other than to say that much of the basic informa- Reproductive capability or success varies by species. Mice tion on reproduction available today stems from research at and rabbits, for example, are prolific producers of offspring. such institutions as Colorado State University, Texas A&M Horses, on the other hand, fall into a category where it is University, and the University of Minnesota. There are many much more chancy. others involved in reproductive research, but much of the in- When horses ran wild, this wasn’t a serious problem. There formation utilized in this article emanated from those three were so many of them that their numbers continued to ex- institutions. pand even though birth rate often was dictated by the avail- ability of food and water. Once the horse was domesticated, The Mare however, organized reproduction became the order of the We’ll begin with the mare because her role in the repro- day. Stables that depend on selling the offspring of stallions ductive process is more complicated than that of the stallion. and mares have an economic stake in breeding success. Yet, Basically, the mare serves four functions: the process continues to be less than perfect, with success 1) She produces eggs or ova; rates hovering in the 65-70% range, and sometimes lower. -
Birth Control Method Options Should Understand the Range and Characteristics of Available Methods
Birth Control FPNTC FAMILY PLANNING Method Options NATIONAL TRAINING CENTER Clients considering their birth control method options should understand the range and characteristics of available methods. Providers can use this chart to help explain the options. Clients should also be counseled about the benefits of delaying sexual activity and reducing risk of STDs by limiting the number of partners and consistently using condoms. What is the How do you How What are Are there Other METHOD risk for use this often is this menstrual side possible side things to pregnancy?* method? used? effects? effects? consider? FEMALE .5 out of 100 STERILIZATION Surgical No menstrual Pain, bleeding, Once Permanent procedure side effects risk of infection MALE .15 out of 100 STERILIZATION Spotting, lighter No estrogen EFFECTIVE .2 out of 100 Up to 6 years LNG IUD or no periods May reduce cramps Placed inside uterus MOST May cause Some pain with No hormones COPPER IUD .8 out of 100 Up to 10 years heavier periods placement May cause cramps No estrogen Placed in Spotting, lighter .05 out of 100 Up to 3 years IMPLANT upper arm or no periods May reduce cramps Shot in arm, Every Spotting, lighter May cause No estrogen 4 out of 100 hip, or under INJECTABLES 3 months or no periods weight gain the skin May reduce cramps Every day at PILL 8 out of 100 Take by mouth May improve acne the same time Can cause EFFECTIVE Nausea, breast May reduce spotting for the tenderness menstrual cramps 9 out of 100 Put on skin Weekly first few months PATCH Risk for VTE Periods may (venous -
Progestin-Only Systemic Hormone Therapy for Menopausal Hot Flashes
EDITORIAL Progestin-only systemic hormone therapy for menopausal hot flashes Clinicians treating postmenopausal hot flashes often recommend “systemic estrogen treatment.” However, progestin-only therapy also can effectively treat hot flashes and is an option for women with a contraindication to estrogen therapy. Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School he field of menopause medi- women. In one study, 133 postmeno- in postmenopausal women with cine is dominated by studies pausal women with an average age an American Heart Association risk T documenting the effective- of 55 years and approximately 3 years score greater than 10% over 10 years.3 ness of systemic estrogen or estro- from their last menstrual period were Additional contraindications to sys- gen-progestin hormone therapy for randomly assigned to 12 weeks of temic estrogen include women with the treatment of hot flashes caused treatment with placebo or micronized cardiac disease who have a throm- by hypoestrogenism. The effective- progesterone 300 mg daily taken at bophilia, such as the Factor V Leiden ness of progestin-only systemic bedtime.1 Mean serum progesterone mutation.4 hormone therapy for the treatment levels were 0.28 ng/mL (0.89 nM) and For women who are at high risk of hot flashes is much less studied 27 ng/mL (86 nM) in the women taking for estrogen-induced cardiovascu- and seldom is utilized in clinical placebo and micronized progesterone, lar events, micronized progesterone practice. -
Actions of Vasoactive Intestinal Peptide on the Rat Adrenal Zona Glomerulosa
51 Actions of vasoactive intestinal peptide on the rat adrenal zona glomerulosa J P Hinson, J R Puddefoot and S Kapas1 Molecular and Cellular Biology Section, Division of Biomedical Sciences, St Bartholomew’s and The Royal London School of Medicine and Dentistry, Queen Mary and Westfield College, Mile End Road, London E1 4NS, UK 1Oral Diseases Research Centre, St Bartholomew’s and The Royal London School of Medicine and Dentistry, 2 Newark Street, London E1 2AT, UK (Requests for offprints should be addressed to J P Hinson) Abstract Previous studies, by this group and others, have shown that The response to VIP in adrenals obtained from rats fed vasoactive intestinal peptide (VIP) stimulates aldosterone a low sodium diet was also investigated. Previous studies secretion, and that the actions of VIP on aldosterone have found that adrenals from animals on a low sodium secretion by the rat adrenal cortex are blocked by â diet exhibit increased responsiveness to VIP. Specific VIP adrenergic antagonists, suggesting that VIP may act by binding sites were identified, although the concentration the local release of catecholamines. The present studies or affinity of binding sites in the low sodium group was not were designed to test this hypothesis further, by measur- significantly different from the controls. In the low sodium ing catecholamine release by adrenal capsular tissue in group VIP was found to increase catecholamine release to response to VIP stimulation. the same extent as in the control group, however, in Using intact capsular tissue it was found that VIP caused contrast to the control group, the adrenal response to VIP a dose-dependent increase in aldosterone secretion, with a was not altered by adrenergic antagonists in the low concomitant increase in both adrenaline and noradrenaline sodium group. -
Affect Breast Cancer Risk
HOW HORMONES AFFECT BREAST CANCER RISK Hormones are chemicals made by the body that control how cells and organs work. Estrogen is a female hormone made mainly in the ovaries. It’s important for sexual development and other body functions. From your first monthly period until menopause, estrogen stimulates normal breast cells. A higher lifetime exposure to estrogen may increase breast cancer risk. For example, your risk increases if you start your period at a young age or go through menopause at a later age. Other hormone-related risks are described below. Menopausal hormone therapy Pills Menopausal hormone therapy (MHT) is The U.S. Food and Drug Administration also known as postmenopausal hormone (FDA) recommends women use the lowest therapy and hormone replacement dose that eases symptoms for the shortest therapy. Many women use MHT pills to time needed. relieve hot flashes and other menopausal Any woman currently taking or thinking symptoms. MHT should be used at the Birth control about taking MHT pills should talk with her lowest dose and for the shortest time pills (oral doctor about the risks and benefits. contraceptives) needed to ease menopausal symptoms. Long-term use can increase breast cancer Vaginal creams, suppositories Current or recent use risk and other serious health conditions. and rings of birth control pills There are 2 main types of MHT pills: slightly increases breast Vaginal forms of MHT do not appear to cancer risk. However, estrogen plus progestin and estrogen increase the risk of breast cancer. However, this risk is quite small alone. if you’ve been diagnosed with breast cancer, vaginal estrogen rings and suppositories are because the risk of Estrogen plus progestin MHT breast cancer for most better than vaginal estrogen creams. -
Informed Consent for Feminizing Hormone Therapy
Informed Consent for Feminizing Hormone Therapy For _________________________ Date of Birth: _____________ Name Used: ____________________ Patient Name as listed in chart Name if different from chart This form will assist you (and your guardian) to think through the expected effects of hormone therapy including possible unwanted side effects. You are encouraged to talk about this treatment with your medical provider and decide if hormone therapy is right for you (your child). By signing this form, you are stating that you have discussed the effects and risks of this medication with your medical provider or a member of the medical team and that you understand and accept these effects and possible risks. You (and your guardian) may ask questions and talk about any concerns you have related to this treatment at any time in this process. Estrogen (usually estradiol) is used to feminize the body (make it look more traditionally female). This medical treatment will reduce some male features and increase some female features of the body. Androgen (testosterone) blockers further decrease the amount of and/or block the effect of testosterone and masculinization of the body. Your medical provider will help decide which form and the amount of estrogen (shots, pills, gels, patches) and androgen blockers (pills, gels, shots, implanted) that are best for you based on your personal needs and any medical or mental health conditions you might have. Each person’s body responds to estrogen differently and it is hard to promise or predict with certainty how each person may respond to treatment. Your medical provider will talk with you throughout the treatment and will help you achieve the best results safely. -
Breastfeeding and Birth Control
Breastfeeding and Birth Control Is it okay for How long does breastfeeding Does it it last or how Does it patients? prevent Birth Control Method and Effectiveness How is it often should it contain How soon can HIV/ at Preventing Pregnancy obtained? be taken? hormones? it be used? STDs? Other considerations? Methods that require a health care provider for insertion or prescription Implant Inserted by Lasts up to Yes Yes; can be used No • A health care provider must remove Small plastic rod that contains a a health care three years the same day as the implant. progestin-only hormone that is provider delivery • The patient may not get a period. inserted under the skin of the arm • Milk supply may decrease and the patient 99% effective may need additional lactation support. IUD, Copper Inserted by Lasts up to 10 No Yes; can be used No • A health care provider must remove A small plastic and copper device a health care years immediately after the IUD. that is inserted inside the uterus provider or at least one • For this method to be inserted at delivery, 99% effective month after delivery the patient will need to be counseled as a part of her prenatal care. IUD, Hormonal Inserted by Lasts between Yes Yes; can be used No • A health care provider must remove the IUD. A small plastic device containing a health care three and five immediately after • For this method to be inserted at delivery, a progestin-only hormone that provider years or at least one the patient will need to be counseled as is inserted inside the uterus month after delivery a part of her prenatal care. -
A Guide to Feminizing Hormones – Estrogen
1 | Feminizing Hormones A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone • Progestin: progesterone Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body. -
Epididymo-Orchitis
Epididymo-orchitis In men over the age of 35 years the most Epididymo-orchitis Bladder common cause is a urine infection – with local Seminal spread of infection from the bladder. This may Epidiymo-orchitis – the basics vesicle Epididymo-orchitisIt is a condition- the basics affecting men characterised by also occur after surgical procedures such as pain and swelling inside the scrotum (ball bag) Prostate Rectum cystoscopy or catheterisation. Epididymo-orchitisand is duea tocondition an infection eitherthat in causesthe: pain and Urethra Occasionally it may also be due to a ‘gut’ swelling inside the scrotum (ball bag). epididymis – tube carrying the sperm from bacterial infection from insertive anal Te s t i s the testicle to the vas deferens and then the intercourse. It is due to an infectionurethra either or water in pipe the: (epididymitis) Rarely epididymo-orchitis may be caused by Penis • epididymistesticle – tube (orchitis) carrying the sperm from the other infections such as mumps or tuberculosis. testicle to theepididymis vas deferensand testicle (epididymo-orchitis)and then the Vas urethra or water pipe (epididymitis) deferens What would I notice if I had epididymo-orchitis? • In men under the age of 35 years it is usually A rapid onset of pain and swelling in one or testicle (orchitis) Epididymis caused by a sexually transmitted infection (STI) sometimes both of your testicles. • epididymisin theand water testicle pipe e.g. (epididymo chlamydia or gonorrhoea.-orchitis) Scrotal Te s t i s Some men may also notice a discharge from Skin Prompt medical assessment is needed to the tip of the water pipe and/or pain on passing In people undermake 35 sure theyou don’t infection have a twisted is testicleoften sexually urine. -
Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment. -
Antiestrogenic Action of Dihydrotestosterone in Mouse Breast
Antiestrogenic action of dihydrotestosterone in mouse breast. Competition with estradiol for binding to the estrogen receptor. R W Casey, J D Wilson J Clin Invest. 1984;74(6):2272-2278. https://doi.org/10.1172/JCI111654. Research Article Feminization in men occurs when the effective ratio of androgen to estrogen is lowered. Since sufficient estrogen is produced in normal men to induce breast enlargement in the absence of adequate amounts of circulating androgens, it has been generally assumed that androgens exert an antiestrogenic action to prevent feminization in normal men. We examined the mechanisms of this effect of androgens in the mouse breast. Administration of estradiol via silastic implants to castrated virgin CBA/J female mice results in a doubling in dry weight and DNA content of the breast. The effect of estradiol can be inhibited by implantation of 17 beta-hydroxy-5 alpha-androstan-3-one (dihydrotestosterone), whereas dihydrotestosterone alone had no effect on breast growth. Estradiol administration also enhances the level of progesterone receptor in mouse breast. Within 4 d of castration, the progesterone receptor virtually disappears and estradiol treatment causes a twofold increase above the level in intact animals. Dihydrotestosterone does not compete for binding to the progesterone receptor, but it does inhibit estrogen-mediated increases of progesterone receptor content of breast tissue cytosol from both control mice and mice with X-linked testicular feminization (tfm)/Y. Since tfm/Y mice lack a functional androgen receptor, we conclude that this antiestrogenic action of androgen is not mediated by the androgen receptor. Dihydrotestosterone competes with estradiol for binding to the cytosolic estrogen receptor of mouse breast, […] Find the latest version: https://jci.me/111654/pdf Antiestrogenic Action of Dihydrotestosterone in Mouse Breast Competition with Estradiol for Binding to the Estrogen Receptor Richard W.